<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046836</url>
  </required_header>
  <id_info>
    <org_study_id>54689</org_study_id>
    <nct_id>NCT03046836</nct_id>
  </id_info>
  <brief_title>Oxytocin, Alcohol Craving, and Intimate Partner Aggression</brief_title>
  <official_title>Effects of Oxytocin on Alcohol Craving and Intimate Partner Aggression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol use disorders (AUD) and intimate partner aggression (IPA) frequently co-occur. There&#xD;
      are significant health and economic burdens associated with AUD and co-occurring IPA, and&#xD;
      little empirical data to guide treatment efforts. The neuropeptide oxytocin may help mitigate&#xD;
      both AUD and IPA. However, clinical data examining oxytocin's effects on human aggression is&#xD;
      scant. The proposed study is designed to address these gaps in the literature by utilizing a&#xD;
      human laboratory paradigm to test the effects of oxytocin on craving and aggression among&#xD;
      couples with AUD and co-occurring IPA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">April 11, 2021</completion_date>
  <primary_completion_date type="Actual">April 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Craving</measure>
    <time_frame>2 hours</time_frame>
    <description>Subjective alcohol craving Measured on a Likert-type scale of 1-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cortisol</measure>
    <time_frame>2 hours</time_frame>
    <description>Salivary cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggression</measure>
    <time_frame>2 hours</time_frame>
    <description>Laboratory-based aggression paradigm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Alcohol Use</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will self-administer 40 IU intranasal Oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will self-administer matching saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>40 IU oxytocin nasal spray</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria indicate that participants must&#xD;
&#xD;
          -  aged 18 or over&#xD;
&#xD;
          -  fluent in English&#xD;
&#xD;
          -  endorse at least one instance of mild or moderate physical IPA with their partner in&#xD;
             the past 6 months as defined by the Revised Conflict Tactics Scale (CTS-2)&#xD;
&#xD;
          -  both partners must be willing to participate&#xD;
&#xD;
          -  one or both partners must meet DSM-V diagnostic criteria for an alcohol use disorder&#xD;
             (AUD). Concurrent substance use disorders (e.g., marijuana) is acceptable provided&#xD;
             alcohol is the participant's primary substance of choice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria include&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  current or history of psychiatric or medical condition that could interfere with&#xD;
             neuroendocrine function (e.g., hematological, endocrine, renal, or pulmonary disease;&#xD;
             synthetic glucocorticoid or exogenous steroid therapy; psychotic, bipolar, eating&#xD;
             disorders)&#xD;
&#xD;
          -  BMI â‰¥ 39&#xD;
&#xD;
          -  current suicidal ideation and intent&#xD;
&#xD;
          -  severe physical or sexual IPA in the past six months as defined by the CTS-2&#xD;
&#xD;
          -  initiation of psychotropic medication in the past 4 weeks&#xD;
&#xD;
          -  acute alcohol withdrawal as indicated by a score of 8 or greater on the CIWA-Ar.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julianne C Flanagan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Julianne Flanagan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Couples</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Aggression</keyword>
  <keyword>Alcohol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

